216 related articles for article (PubMed ID: 31590928)
1. Variants in oxidative stress-related genes affect the chemosensitivity through Nrf2-mediated signaling pathway in biliary tract cancer.
Zhan M; Wang H; Xu SW; Yang LH; Chen W; Zhao SX; Shen H; Liu Q; Yang RM; Wang J
EBioMedicine; 2019 Oct; 48():143-160. PubMed ID: 31590928
[TBL] [Abstract][Full Text] [Related]
2. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
3. NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
Kiesslich T; Mayr C; Neureiter D
EBioMedicine; 2019 Nov; 49():9-10. PubMed ID: 31648982
[No Abstract] [Full Text] [Related]
4. The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Mayr C; Helm K; Jakab M; Ritter M; Shrestha R; Makaju R; Wagner A; Pichler M; Beyreis M; Staettner S; Jaeger T; Klieser E; Kiesslich T; Neureiter D
Hum Pathol; 2018 Feb; 72():117-126. PubMed ID: 29133140
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Noda T; Eguchi H; Sakamoto T; Iwagami Y; Yamada D; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Ann Surg Oncol; 2018 Nov; 25(12):3728-3737. PubMed ID: 30105440
[TBL] [Abstract][Full Text] [Related]
6. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
7. Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer.
Meng LQ
Tumour Biol; 2014 Dec; 35(12):12497-508. PubMed ID: 25217982
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
9. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer.
Kitamura T; Srivastava J; DiGiovanni J; Kiguchi K
Mol Carcinog; 2015 Jun; 54(6):459-72. PubMed ID: 24839254
[TBL] [Abstract][Full Text] [Related]
10. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.
Nguyen Ho-Bouldoires TH; Clapéron A; Mergey M; Wendum D; Desbois-Mouthon C; Tahraoui S; Fartoux L; Chettouh H; Merabtene F; Scatton O; Gaestel M; Praz F; Housset C; Fouassier L
Free Radic Biol Med; 2015 Dec; 89():34-46. PubMed ID: 26169728
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
[TBL] [Abstract][Full Text] [Related]
14. FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling.
Guan L; Zhang L; Gong Z; Hou X; Xu Y; Feng X; Wang H; You H
Hepatology; 2016 Jun; 63(6):1914-27. PubMed ID: 26857210
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation.
Yu KD; Huang AJ; Fan L; Li WF; Shao ZM
Cancer Res; 2012 Jan; 72(2):408-19. PubMed ID: 22147260
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
[TBL] [Abstract][Full Text] [Related]
17. Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance.
Payandeh Z; Pirpour Tazehkand A; Barati G; Pouremamali F; Kahroba H; Baradaran B; Samadi N
Biochimie; 2020 Dec; 179():32-45. PubMed ID: 32946993
[TBL] [Abstract][Full Text] [Related]
18. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.
Li PC; Tu MJ; Ho PY; Jilek JL; Duan Z; Zhang QY; Yu AX; Yu AM
Drug Metab Dispos; 2018 Jan; 46(1):2-10. PubMed ID: 29061583
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment.
Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN
FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768
[TBL] [Abstract][Full Text] [Related]
20. Genetic risk score combining six genetic variants associated with the cellular NRF2 expression levels correlates with Type 2 diabetes in the human population.
Shin JH; Lee KM; Shin J; Kang KD; Nho CW; Cho YS
Genes Genomics; 2019 May; 41(5):537-545. PubMed ID: 30767168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
